Adaptin Bio (APTN) Equity Ratio (2022 - 2026)

Adaptin Bio has disclosed Equity Ratio across 5 years of filings, most recently posting 2.51 for Q1 2026.

• Quarterly Equity Ratio fell 511.2% year-over-year to 2.51 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 2.51 (down 511.2% YoY) and the FY2025 annual result came in at 2.41, up 85.95% from the prior year.
• Equity Ratio slipped to 2.51 in Q1 2026, from 2.41 in the prior quarter.
• Across five years, Equity Ratio topped out at 0.61 in Q1 2025 and bottomed at 10072.3 in Q3 2024.
• The 5-year median for Equity Ratio is 35.87 (2024), against an average of 1918.93.
• Year-over-year, Equity Ratio sank 4760.78% in 2024 and jumped 100.02% in 2025.
• Adaptin Bio's Equity Ratio stood at 54.61 in 2022, then slumped by 4610.89% to 2572.52 in 2023, then jumped by 99.33% to 17.13 in 2024, then jumped by 85.95% to 2.41 in 2025, then declined by 4.53% to 2.51 in 2026.
• According to Business Quant data, Equity Ratio over the past three periods registered 2.51, 2.41, and 0.9 for Q1 2026, Q4 2025, and Q3 2025 respectively.